Castle Biosciences stock gets Buy upgrade as EADV data are presented

Published on 10/05/2026 at 06:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Castle Biosciences stock received a Buy rating on September 26, 2026. EADV data covered 2,799 patients and 99.60 percent survival.

CSTL, US14843C1053, Illustration mit AI erstellt.

Wall Street Zen upgraded Castle Biosciences stock from Hold to Buy on September 26, 2026, according to MarketBeat. The company then presented new DecisionDx-Melanoma findings at the European Academy of Dermatology and Venereology Congress, per PR Newswire on September 30, 2026.

Study size gives the data weight

The late-breaking study included 2,799 patients across 29 U.S. centers. Among 565 eligible patients with low-risk results who did not undergo sentinel lymph node biopsy, five-year recurrence-free survival reached 99.60 percent, according to PR Newswire.

The same release reported a 4.40 percent observed sentinel lymph node positivity rate among 676 low-risk patients who underwent the procedure. High-risk patients recorded a 22.80 percent rate, creating an 18.40 percentage-point gap between the two groups.

Revenue beat remains a second pillar

Castle Biosciences reported USD 103.5 million of revenue in the second quarter of 2026, versus USD 86.2 million expected by FactSet, according to MarketScreener. That comparison implies revenue exceeded the estimate by USD 17.3 million, while adjusted loss per share was USD 0.07 versus an expected USD 0.41 loss.

The financial profile therefore combines expanding clinical evidence with commercial execution. The Q2 2026 operating cash flow was USD 15.2 million, and cash stood at USD 62.1 million at June 30, 2026.

Market value and next report

Castle Biosciences had a market capitalization of USD 1.1 billion and a 52-week range of USD 17.72 to USD 44.28 as of October 2, 2026. The next earnings report is scheduled for November 1, 2026, according to AltIndex.